What is Demetrix?
Founded in 2015, Demetrix operates at the vanguard of synthetic biology, specializing in the production of rare, high-purity cannabinoids. The company utilizes sophisticated fermentation technology to synthesize compounds that are traditionally difficult to extract, offering a scalable and sustainable alternative for both pharmaceutical and consumer-facing industries. With a multidisciplinary team of experts spanning R&D, regulatory affairs, and commercialization, Demetrix is uniquely positioned to bridge the gap between laboratory-scale innovation and industrial-scale manufacturing. Their market position is defined by a commitment to scientific rigor, ensuring that their health and wellness products meet the stringent quality standards required for global distribution.
How much funding has Demetrix raised?
Demetrix has raised a total of $61M across 2 funding rounds:
Angel/Seed
$11M
Series A
$50M
Angel/Seed (2019): $11M with participation from Horizons Ventures
Series A (2019): $50M led by Horizons Ventures and Tuatara Capital
Key Investors in Demetrix
Horizons Ventures
A venture capital firm with over two decades of experience, specializing in transforming early-stage startups into successful enterprises through active involvement and equity financing.
Tuatara Capital
A dedicated investment firm focused on supporting innovative entrepreneurs by providing foundational partnerships and strategic guidance throughout the business lifecycle.
What's next for Demetrix?
With the successful closure of this major strategic investment, Demetrix is poised to accelerate its commercialization roadmap. The company is expected to prioritize the scaling of its fermentation infrastructure to meet the growing demand for high-purity cannabinoids in the pharmaceutical sector. Furthermore, the firm will likely focus on navigating complex regulatory landscapes to secure market access for its diverse product pipeline. By maintaining its focus on scientific excellence and operational efficiency, Demetrix is well-positioned to capture significant market share, potentially setting new benchmarks for quality and consistency in the rapidly evolving biotechnology landscape.
See full Demetrix company page
